New PET scan method could better track brain tumor treatment success

NCT ID NCT07017790

Completed Knowledge-focused Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a special type of PET scan (amino acid PET) can better measure how well IDH inhibitor drugs are working in patients with a certain type of brain tumor (IDH-mutated glioma). The researchers compared the PET scan results with standard MRI scans in 22 patients. The goal was to see if the PET scan could detect treatment response earlier or more accurately than MRI.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18-fluoroDopa (amino acid PET tracer)
What this could lead to: If successful, this could establish amino acid PET as a more accurate way to assess whether IDH inhibitor treatments are working in patients with IDH-mutated gliomas.
What could go wrong: This is a small, completed observational study with only 22 patients. It does not test a new treatment itself, so any benefits are limited to improving how we measure response, not directly improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

Contacts and locations

Locations

CHRU of NANCY

Vandœuvre-lès-Nancy, 54511, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.